UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Emollient enhancement of the skin barrier from birth offers effective atopic dermatitis prevention

Journal of allergy and clinical immunology, 2014-10, Vol.134 (4), p.818-823

2014

Volltextzugriff (PDF)

Two Phase 3 Trials of Dupilumab versus Placebo in Atopic Dermatitis

The New England journal of medicine, 2016-12, Vol.375 (24), p.2335-2348

2016

Volltextzugriff (PDF)

Atopic dermatitis epidemiology and unmet need in the United Kingdom

The Journal of dermatological treatment, 2020-11, Vol.31 (8), p.801-809

2020

Volltextzugriff (PDF)

Daily emollient during infancy for prevention of eczema: the BEEP randomised controlled trial

The Lancet (British edition), 2020-03, Vol.395 (10228), p.962-972

2020

Volltextzugriff (PDF)

Efficacy and safety of dupilumab with concomitant topical corticosteroids in children 6 to 11 years old with severe atopic dermatitis: A randomized, double-blinded, placebo-controlled phase 3 trial

Journal of the American Academy of Dermatology, 2020-11, Vol.83 (5), p.1282-1293

2020

Volltextzugriff (PDF)

Real-Time Infrared Spectroscopic Measurement of Natural Moisturizing Factor

Journal of investigative dermatology, 2023-04, Vol.143 (4), p.676-679.e5

2023

Volltextzugriff (PDF)

Type 2 Inflammation Contributes to Skin Barrier Dysfunction in Atopic Dermatitis

JID innovations, 2022-09, Vol.2 (5), p.100131-100131, Article 100131

2022

Volltextzugriff (PDF)

Dupilumab improves patient-reported symptoms and health-related quality of life in children aged 6-11 years with severe atopic dermatitis

British journal of dermatology (1951), 2023-07, Vol.189 (2), p.238-240

2023

Volltextzugriff (PDF)

Adverse effects of topical glucocorticosteroids

Journal of the American Academy of Dermatology, 2006, Vol.54 (1), p.1-15

2006

Volltextzugriff (PDF)

Dupilumab in children aged 6 months to younger than 6 years with uncontrolled atopic dermatitis: a randomised, double-blind, placebo-controlled, phase 3 trial

The Lancet (British edition), 2022-09, Vol.400 (10356), p.908-919

2022

Volltextzugriff (PDF)

Safety and efficacy of amlitelimab, a fully human nondepleting, noncytotoxic anti-OX40 ligand monoclonal antibody, in atopic dermatitis: results of a phase IIa randomized placebo-controlled trial

British journal of dermatology (1951), 2023-10, Vol.189 (5), p.531-539

2023

Volltextzugriff (PDF)

Enhancement of stratum corneum lipid structure improves skin barrier function and protects against irritation in adults with dry, eczema‐prone skin

British journal of dermatology (1951), 2022-05, Vol.186 (5), p.875-886

2022

Volltextzugriff (PDF)

The Effect of Water Hardness on Surfactant Deposition after Washing and Subsequent Skin Irritation in Atopic Dermatitis Patients and Healthy Control Subjects

Journal of investigative dermatology, 2018-01, Vol.138 (1), p.68-77

2018

Volltextzugriff (PDF)

Characterization of skin barrier defects using infrared spectroscopy in patients with atopic dermatitis

Clinical and experimental dermatology, 2024-04, Vol.49 (5), p.466-477

2024

Volltextzugriff (PDF)

Association between skin barrier development and early-onset atopic dermatitis: A longitudinal birth cohort study

Journal of allergy and clinical immunology, 2024-03, Vol.153 (3), p.732-741.e8

2024

Volltextzugriff (PDF)

Clinically Meaningful Responses to Dupilumab Among Children Aged 6 Months to 5 Years with Moderate-to-severe Atopic Dermatitis who did Not Achieve Clear or Almost Clear Skin According to the Investigator's Global Assessment: A Post Hoc Analysis of a Phase 3 Trial

Acta dermato-venereologica, 2024-02, Vol.104, p.adv13467-adv13467

2024

Volltextzugriff (PDF)

When does atopic dermatitis warrant systemic therapy? Recommendations from an expert panel of the International Eczema Council

Journal of the American Academy of Dermatology, 2017-10, Vol.77 (4), p.623-633

2017

Volltextzugriff (PDF)

Dupilumab improves patient-reported symptoms of atopic dermatitis, symptoms of anxiety and depression, and health-related quality of life in moderate-to-severe atopic dermatitis: analysis of pooled data from the randomized trials SOLO 1 and SOLO 2

The Journal of dermatological treatment, 2020-08, Vol.31 (6), p.606-614

2020

Volltextzugriff (PDF)

Dupilumab Treatment in Pediatric Patients Aged 6-11 Years with Severe Atopic Dermatitis Whose Disease Is Not Adequately Controlled: A Review

Drug design, development and therapy, 2024-01, Vol.18, p.277-289

2024

Volltextzugriff (PDF)

Effects of a pH-Regulating Emollient Cream in Mild Atopic Dermatitis Patients with Moderate Localised Lesions

Skin pharmacology and physiology, 2024-08

2024

Volltextzugriff (PDF)

Vehicles for atopic dermatitis therapies: more than just a placebo

The Journal of dermatological treatment, 2022-03, Vol.33 (2), p.685-698

2022

Volltextzugriff (PDF)

Recommendations from a European Roundtable Meeting on Best Practice Healthy Infant Skin Care

Pediatric dermatology, 2016-05, Vol.33 (3), p.311-321

2016

Volltextzugriff (PDF)

New perspectives on epidermal barrier dysfunction in atopic dermatitis: Gene–environment interactions

Journal of allergy and clinical immunology, 2006-07, Vol.118 (1), p.3-21

2006

Volltextzugriff (PDF)

Epidermal Barrier Dysfunction in Atopic Dermatitis

Journal of investigative dermatology, 2009-08, Vol.129 (8), p.1892-1908

2009

Volltextzugriff (PDF)

Long-Term Efficacy and Safety of Dupilumab in Adolescents with Moderate-to-Severe Atopic Dermatitis: Results Through Week 52 from a Phase III Open-Label Extension Trial (LIBERTY AD PED-OLE)

American journal of clinical dermatology, 2022-05, Vol.23 (3), p.365-383

2022

Volltextzugriff (PDF)

1 – 25 von 373

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(343)
Mit Volltextzugriff
(297)

Publikationsform

3 weitere anzeigen...

Weniger anzeigen...

Sprache

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(21)
... seit 30 Tagen
(8)

Menü

Weitere Dienste

Einstellungen

Emollient enhancement of the skin barrier from birth offers effective atopic dermatitis prevention

Two Phase 3 Trials of Dupilumab versus Placebo in Atopic Dermatitis

Atopic dermatitis epidemiology and unmet need in the United Kingdom

Daily emollient during infancy for prevention of eczema: the BEEP randomised controlled trial

Efficacy and safety of dupilumab with concomitant topical corticosteroids in children 6 to 11 years old with severe atopic dermatitis: A randomized, double-blinded, placebo-controlled phase 3 trial

Real-Time Infrared Spectroscopic Measurement of Natural Moisturizing Factor

Type 2 Inflammation Contributes to Skin Barrier Dysfunction in Atopic Dermatitis

Dupilumab improves patient-reported symptoms and health-related quality of life in children aged 6-11 years with severe atopic dermatitis

Adverse effects of topical glucocorticosteroids

Dupilumab in children aged 6 months to younger than 6 years with uncontrolled atopic dermatitis: a randomised, double-blind, placebo-controlled, phase 3 trial

Safety and efficacy of amlitelimab, a fully human nondepleting, noncytotoxic anti-OX40 ligand monoclonal antibody, in atopic dermatitis: results of a phase IIa randomized placebo-controlled trial

Enhancement of stratum corneum lipid structure improves skin barrier function and protects against irritation in adults with dry, eczema‐prone skin

The Effect of Water Hardness on Surfactant Deposition after Washing and Subsequent Skin Irritation in Atopic Dermatitis Patients and Healthy Control Subjects

Characterization of skin barrier defects using infrared spectroscopy in patients with atopic dermatitis

Association between skin barrier development and early-onset atopic dermatitis: A longitudinal birth cohort study

Clinically Meaningful Responses to Dupilumab Among Children Aged 6 Months to 5 Years with Moderate-to-severe Atopic Dermatitis who did Not Achieve Clear or Almost Clear Skin According to the Investigator's Global Assessment: A Post Hoc Analysis of a Phase 3 Trial

When does atopic dermatitis warrant systemic therapy? Recommendations from an expert panel of the International Eczema Council

Dupilumab improves patient-reported symptoms of atopic dermatitis, symptoms of anxiety and depression, and health-related quality of life in moderate-to-severe atopic dermatitis: analysis of pooled data from the randomized trials SOLO 1 and SOLO 2

Dupilumab Treatment in Pediatric Patients Aged 6-11 Years with Severe Atopic Dermatitis Whose Disease Is Not Adequately Controlled: A Review

Effects of a pH-Regulating Emollient Cream in Mild Atopic Dermatitis Patients with Moderate Localised Lesions

Vehicles for atopic dermatitis therapies: more than just a placebo

Recommendations from a European Roundtable Meeting on Best Practice Healthy Infant Skin Care

New perspectives on epidermal barrier dysfunction in atopic dermatitis: Gene–environment interactions

Epidermal Barrier Dysfunction in Atopic Dermatitis

Long-Term Efficacy and Safety of Dupilumab in Adolescents with Moderate-to-Severe Atopic Dermatitis: Results Through Week 52 from a Phase III Open-Label Extension Trial (LIBERTY AD PED-OLE)

Suchergebnisse filtern